Second-degree Heart Block Caused by Itolizumab-induced Infusion Reaction in COVID-19
Abhyuday Kumar, Neeraj Kumar, Dharani Lenin, Amarjeet Kumar, Shaheen Ahmad
Keywords :
COVID-19, Heart block, Itolizumab,Adverse drug reaction
Citation Information :
Kumar A, Kumar N, Lenin D, Kumar A, Ahmad S. Second-degree Heart Block Caused by Itolizumab-induced Infusion Reaction in COVID-19. Indian J Crit Care Med 2021; 25 (4):474-475.
Nair P, Melarkode R, Rajkumar D, Montero E. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol 2010;162(1):116–130. DOI: 10.1111/j.1365-2249.2010.04235.x.
Ministry of Health and Family Welfare, India. DCGI gives Nod for restricted emergency use to Itolizumab for moderate to severe COVID-19 patients. Press release. Available from: https://pib.gov.in/PressReleasePage.aspx?PRID=1637926. Accessed 22 December 2020.
Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12(5):601–609. DOI: 10.1634/theoncologist.12-5-601.